IntroductionCancer is considered the second most common disease causing death (Tuncer, 2008). It is estimated that 19.3 million new cancer cases will be detected per year by 2025. The incidence, morbidity, and mortality of cancer are expected to be much higher in developing countries such as Turkey. Efforts to cure cancer or reduce its occurrence will be significantly important (Tuncer, 2008).Although many anticancer drugs have been used to treat cancer, they have some limitations, such as side effects, tumor specificity, and tumor cell resistance (Roche, 2002). Therefore, new anticancer drug candidates with few or no side effects need to be developed as alternatives to current chemotherapeutic drugs. Metals and metal compounds have been used in medicine as antiprotozoal, antiulcer, antiarthritic, antimalarial, antimicrobial, and anticancer drugs (Avendańo, 2008). Nowadays, the application of metal complexes in medicine is being investigated very extensively. Thati et al. (2007) reported that silver complexes of coumarin derivatives possess anticancer activity against certain types of cancer. Zhu et al. (2003) reported that silver carboxylate dimers exert anticancer activity against human carcinoma cells. The phosphine Abstract: The discovery of anticancer activity in cisplatin triggered the development of novel drugs containing metals such as platinum or ruthenium. Extremely diverse structural chemistry and the interaction of metal complexes with biomolecules resulted in the exploration of novel metal complexes with drug potential. In the present study, the anticancer and cytotoxic activities and the mechanisms of action were investigated for C 16 H 34 N 8 O 5 Ag 2 Cd (AN1) and C 11 H 16 N 7 O 2 Ag 3 Ni (AN7), 2 newly synthesized dicyanidoargentate(I) complexes. The anticancer and cytotoxic activities of AN1 and AN7 on several cancer cell lines were tested by cell proliferation and cytotoxic activity assays, respectively. The apoptotic and replication inhibitory potentials of the compounds were investigated using terminal deoxynucleotidyl transferase dUTP nick and labeling (TUNEL) and DNA topoisomerase inhibition assays. AN1 and AN7 showed significant (P < 0.05) anticancer activity and lower cytotoxicity against all cell lines tested. The TUNEL assay results indicated that AN1 and AN7 may inhibit cell proliferation by inducing apoptosis. The compounds showed very significant DNA topoisomerase I inhibitory activity. Based on the results, it is suggested that compounds AN1 and AN7 are potential anticancer drug candidates.